Another study on KRAS mutant lung adenocarcinoma identified UHRF1 as a critical target for cardiac glycosides, potent DSB repair inhibitors, in sensitizing KRAS mutant lung cancer to chemotherapy [68]. This evidence concerns the gene UHRF1 and lung cancer.